BACKGROUND & AIMS: The anti-tumor necrosis factor (TNF) antibodies infliximab, adalimumab, and certolizumab pegol have proven clinical efficacy in Crohn's disease. Here, we assessed the effects of anti-TNF antibodies on apoptosis in inflammatory bowel disease (IBD). METHODS: CD14(+) macrophages and CD4(+) T cells were isolated from peripheral blood and lamina propria mononuclear cells from patients with IBD and control patients. Cell surface markers and apoptosis were assessed by immunohistology and fluorescence-activated cell sorting techniques. RESULTS: Lamina propria CD14(+) macrophages showed significantly more frequent and higher membrane-bound TNF (mTNF) expression than CD4(+) T cells in IBD, whereas mTNF-dependent signaling proteins such as TNF receptor (TNFR) 2, TNFR-associated factor (TRAF) 2, and nuclear factor κB were induced in IBD mucosal CD4(+) T cells. Most anti-TNF antibodies did not induce T-cell apoptosis in purified peripheral or mucosal CD4(+) T cells. However, in contrast to etanercept, administration of all clinically effective anti-TNF antibodies resulted in a significant induction of T-cell apoptosis in IBD when lamina propria CD4(+) T cells expressing TNFR2(+) were cocultured with mTNF(+) CD14(+) intestinal macrophages. In contrast, no effects in control patients were noted. T-cell apoptosis in IBD occurred in vivo after treatment with adalimumab and infliximab, was critically dependent on TNFR2 signaling, and could be prevented via interleukin-6 signal transduction. Blockade of interleukin-6R signaling augmented anti-TNF-induced T-cell apoptosis in IBD. CONCLUSIONS: Clinically effective anti-TNF antibodies are able to induce T-cell apoptosis in IBD only when mucosal TNFR2(+) T cells are cocultured with mTNF-expressing CD14(+) macrophages. The finding that anti-TNF antibodies induce apoptosis indirectly by targeting the mTNF/TNFR2 pathway may have important implications for the development of new therapeutic strategies in IBD.
BACKGROUND & AIMS: The anti-tumor necrosis factor (TNF) antibodies infliximab, adalimumab, and certolizumab pegol have proven clinical efficacy in Crohn's disease. Here, we assessed the effects of anti-TNF antibodies on apoptosis in inflammatory bowel disease (IBD). METHODS:CD14(+) macrophages and CD4(+) T cells were isolated from peripheral blood and lamina propria mononuclear cells from patients with IBD and control patients. Cell surface markers and apoptosis were assessed by immunohistology and fluorescence-activated cell sorting techniques. RESULTS: Lamina propria CD14(+) macrophages showed significantly more frequent and higher membrane-bound TNF (mTNF) expression than CD4(+) T cells in IBD, whereas mTNF-dependent signaling proteins such as TNF receptor (TNFR) 2, TNFR-associated factor (TRAF) 2, and nuclear factor κB were induced in IBD mucosal CD4(+) T cells. Most anti-TNF antibodies did not induce T-cell apoptosis in purified peripheral or mucosal CD4(+) T cells. However, in contrast to etanercept, administration of all clinically effective anti-TNF antibodies resulted in a significant induction of T-cell apoptosis in IBD when lamina propria CD4(+) T cells expressing TNFR2(+) were cocultured with mTNF(+) CD14(+) intestinal macrophages. In contrast, no effects in control patients were noted. T-cell apoptosis in IBD occurred in vivo after treatment with adalimumab and infliximab, was critically dependent on TNFR2 signaling, and could be prevented via interleukin-6 signal transduction. Blockade of interleukin-6R signaling augmented anti-TNF-induced T-cell apoptosis in IBD. CONCLUSIONS: Clinically effective anti-TNF antibodies are able to induce T-cell apoptosis in IBD only when mucosal TNFR2(+) T cells are cocultured with mTNF-expressing CD14(+) macrophages. The finding that anti-TNF antibodies induce apoptosis indirectly by targeting the mTNF/TNFR2 pathway may have important implications for the development of new therapeutic strategies in IBD.
Authors: J Grundström; L Linton; S Thunberg; H Forsslund; I Janczewska; R Befrits; M van Hage; G Gafvelin; M Eberhardson Journal: Clin Exp Immunol Date: 2012-08 Impact factor: 4.330
Authors: C Lutz; M Mozaffari; V Tosevski; M Caj; P Cippà; B L McRae; C L Graff; G Rogler; M Fried; M Hausmann Journal: Clin Exp Immunol Date: 2015-05-19 Impact factor: 4.330
Authors: Christopher S Smillie; Moshe Biton; Jose Ordovas-Montanes; Keri M Sullivan; Grace Burgin; Daniel B Graham; Rebecca H Herbst; Noga Rogel; Michal Slyper; Julia Waldman; Malika Sud; Elizabeth Andrews; Gabriella Velonias; Adam L Haber; Karthik Jagadeesh; Sanja Vickovic; Junmei Yao; Christine Stevens; Danielle Dionne; Lan T Nguyen; Alexandra-Chloé Villani; Matan Hofree; Elizabeth A Creasey; Hailiang Huang; Orit Rozenblatt-Rosen; John J Garber; Hamed Khalili; A Nicole Desch; Mark J Daly; Ashwin N Ananthakrishnan; Alex K Shalek; Ramnik J Xavier; Aviv Regev Journal: Cell Date: 2019-07-25 Impact factor: 41.582
Authors: Shrinivas Bishu; Mohammed El Zaatari; Atsushi Hayashi; Guoqing Hou; Nicole Bowers; Jami Kinnucan; Beth Manoogian; Michelle Muza-Moons; Min Zhang; Helmut Grasberger; Charlie Bourque; Weiping Zou; Peter D R Higgins; Jason R Spence; Ryan W Stidham; Nobuhiko Kamada; John Y Kao Journal: J Crohns Colitis Date: 2019-07-25 Impact factor: 9.071
Authors: Raja Atreya; Helmut Neumann; Clemens Neufert; Maximilian J Waldner; Ulrike Billmeier; Yurdagül Zopf; Marcus Willma; Christine App; Tino Münster; Hermann Kessler; Stefanie Maas; Bernd Gebhardt; Ralph Heimke-Brinck; Eva Reuter; Frank Dörje; Tilman T Rau; Wolfgang Uter; Thomas D Wang; Ralf Kiesslich; Michael Vieth; Ewald Hannappel; Markus F Neurath Journal: Nat Med Date: 2014-02-23 Impact factor: 53.440
Authors: Liping Su; Sam C Nalle; Le Shen; Emily S Turner; Gurminder Singh; Lydia A Breskin; Ekaterina A Khramtsova; Galina Khramtsova; Pei-Yun Tsai; Yang-Xin Fu; Clara Abraham; Jerrold R Turner Journal: Gastroenterology Date: 2013-04-22 Impact factor: 22.682